Commercial Readiness with ImmunityBio's Bobby Reddy, M.D.

ImmunityBio's efforts to revolutionize bladder cancer treatment are discussed with Dr. Sandeep Bobby Reddy, Chief Medical Officer, whose lead candidate, Anktiva, is nearing potential FDA approval. Dr. Reddy recounts his initial interest in Anktiva, driven by its potential to enhance immune response without the severe toxicities of previous treatments like high-dose interleukin-2. The conversation highlights the BCG-unresponsive trial's success, showing a 71% complete response rate and durable remission exceeding three years. Dr. Reddy also shares insights on navigating the BLA submission process, emphasizing the importance of teamwork, regulatory agency collaboration, and adapting to the evolving regulatory landscape. Beyond bladder cancer, ImmunityBio's broader pipeline includes cell therapy and vaccine programs, aiming for synergistic cancer treatments.